These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 22583734)

  • 1. A case of rapid improvement of severe psoriasis during molecular-targeted therapy using an epidermal growth factor receptor tyrosine kinase inhibitor for metastatic lung adenocarcinoma.
    Oyama N; Kaneko F; Togashi A; Yamamoto T
    J Am Acad Dermatol; 2012 Jun; 66(6):e251-3. PubMed ID: 22583734
    [No Abstract]   [Full Text] [Related]  

  • 2. Improvement of psoriasis in a lung cancer patient treated with erlotinib.
    Giroux Leprieur E; Friard S; Couderc LJ
    Eur J Dermatol; 2010; 20(2):243-4. PubMed ID: 20123646
    [No Abstract]   [Full Text] [Related]  

  • 3. Improvement of psoriasis and cutaneous side-effects during tyrosine kinase inhibitor therapy for renal metastatic adenocarcinoma. A role for epidermal growth factor receptor (EGFR) inhibitors in psoriasis?
    Wierzbicka E; Tourani JM; Guillet G
    Br J Dermatol; 2006 Jul; 155(1):213-4. PubMed ID: 16792781
    [No Abstract]   [Full Text] [Related]  

  • 4. Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.
    Technol Eval Cent Assess Program Exec Summ; 2011 Mar; 25(6):1-5. PubMed ID: 21638942
    [No Abstract]   [Full Text] [Related]  

  • 5. Two cases of psoriasis responding to erlotinib: time to revisiting inhibition of epidermal growth factor receptor in psoriasis therapy?
    Overbeck TR; Griesinger F
    Dermatology; 2012; 225(2):179-82. PubMed ID: 23095682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
    Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ
    Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gefitinib as an effective therapy for advanced hepatocellular carcinoma with lung metastasis?
    Chen WC; Chen W; Tseng GC; Lai HC; Shih CM; Hsia TC
    Liver Int; 2010 Nov; 30(10):1548-9. PubMed ID: 20345702
    [No Abstract]   [Full Text] [Related]  

  • 8. Different responses to gefitinib in lung adenocarcinoma coexpressing mutant- and wild-type epidermal growth factor receptor genes.
    Chou WC; Huang SF; Yeh KY; Wang HM; Liu MY; Hsieh JJ; Cheung YC; Chang JW
    Jpn J Clin Oncol; 2006 Aug; 36(8):523-6. PubMed ID: 16803841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor targeted therapy with gefitinib in locally advanced and metastatic primary lung adenocarcinoma.
    Liam CK; Pang YK; Leow CH
    Respirology; 2006 May; 11(3):287-91. PubMed ID: 16635086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Good response to gefitinib for lung adenocarcinoma with hyperamylasemia: a case report.
    Ko HW; Tsai YH; Yu CT; Huang CY; Chen CH
    Chang Gung Med J; 2008; 31(6):606-11. PubMed ID: 19241901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern.
    Wu SG; Chang YL; Hsu YC; Wu JY; Yang CH; Yu CJ; Tsai MF; Shih JY; Yang PC
    Oncologist; 2008 Dec; 13(12):1276-84. PubMed ID: 19060236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High efficacy of first-line gefitinib in non-Asian patients with EGFR-mutated lung adenocarcinoma.
    Moiseyenko VM; Procenko SA; Levchenko EV; Barchuk AS; Moiseyenko FV; Iyevleva AG; Mitiushkina NV; Togo AV; Semionov II; Ivantsov AO; Matsko DE; Imyanitov EN
    Onkologie; 2010; 33(5):231-8. PubMed ID: 20502057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese.
    Uramoto H; Sugio K; Oyama T; Ono K; Sugaya M; Yoshimatsu T; Hanagiri T; Morita M; Yasumoto K
    Lung Cancer; 2006 Jan; 51(1):71-7. PubMed ID: 16198442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
    Yi HG; Kim HJ; Kim YJ; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Kim CS; Heo DS; Bang YJ
    Lung Cancer; 2009 Jul; 65(1):80-4. PubMed ID: 19059670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment with erlotinib after gefitinib-induced interstitial lung disease: a case report and literature review.
    Koma Y; Matsuoka H; Yoshimatsu H; Suzuki Y
    Int J Clin Pharmacol Ther; 2012 Oct; 50(10):760-4. PubMed ID: 22853866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Perspectives and future developments of epidermal growth factor receptors inhibitors].
    Soria JC
    Rev Pneumol Clin; 2007 Jan; 63(1 Pt 2):2S18-20. PubMed ID: 17242641
    [No Abstract]   [Full Text] [Related]  

  • 17. Response to pemetrexed chemotherapy in lung adenocarcinoma-bronchioloalveolar carcinoma insensitive to erlotinib.
    Manson GV; Ma PC
    Clin Lung Cancer; 2010 Jan; 11(1):57-60. PubMed ID: 20085869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucoepidermoid carcinoma of lung: potential target of EGFR-directed treatment.
    Han SW; Kim HP; Jeon YK; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Heo DS; Bang YJ; Kim TY
    Lung Cancer; 2008 Jul; 61(1):30-4. PubMed ID: 18192072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib.
    Zhang L; Yuan X; Chen Y; Du XJ; Yu S; Yang M
    Gene; 2013 Mar; 517(1):60-4. PubMed ID: 23313300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous side-effects of epidermal growth factor receptor-tyrosine kinase inhibitor (TKI) in the treatment of lung cancer: description and its management.
    Ong CK; Tan WC; Chan LC; Abdul Razak M
    Med J Malaysia; 2012 Apr; 67(2):222-3. PubMed ID: 22822651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.